SCHEMBL30764754

SCHEMBL30764754

O=C(Cc1ccc(Cl)cc1)N1CC2(CN(CCc3cccc(F)c3)C2)C1

nearest known ligand 0.52

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 2/20 0.46
SLC6A3 Q01959 1/20 0.45
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
CNR1 P21554 1/20 0.42
CYP2D6 P10635 1/20 0.41
TSHR P16473 1/20 0.41
SIGMAR1 Q99720 2/20 0.41
OPRM1 P35372 1/20 0.41
KCNH2 Q12809 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
GFER P55789 1/20 0.40
ATM Q13315 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30764736 0.92 HSD11B1 (0.49) HSD11B1SLC6A3SIGMAR1
SCHEMBL30764734 0.88 KMT2A (0.54) HSD11B1MEN1KMT2AKCNH2GFER
SCHEMBL30764764 0.87 ALDH1A1 (0.49) HSD11B1CNR1SIGMAR1
SCHEMBL30764743 0.86 MEN1 (0.51) HSD11B1MEN1KMT2ACNR1CYP2D6
SCHEMBL30764731 0.81 HSD11B1 (0.56) HSD11B1MEN1KMT2AKCNH2
SCHEMBL30764739 0.81 MEN1 (0.52) HSD11B1MEN1KMT2ACNR1CYP2D6
SCHEMBL30764724 0.81 HSD11B1 (0.51) HSD11B1MEN1KMT2AKCNH2CYP2C19
SCHEMBL30764749 0.79 HSD11B1 (0.49) HSD11B1MEN1KMT2ASIGMAR1KCNH2
SCHEMBL30764719 0.78 SMN1; SMN2 (0.53) HSD11B1SIGMAR1
SCHEMBL30764707 0.78 HSD11B1 (0.55) HSD11B1MEN1KMT2ASIGMAR1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568968-A1 (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS Remynd N.V. (BE) 2025-06-18 EP disclosed
WO-2024033479-A1 (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS REMYND N.V. (BE) 2024-02-15 WO disclosed